Marc Lallemant1, Sophie Le Coeur, Wasna Sirirungsi, Tim R Cressey, Nicole Ngo-Giang-Huong, Patrinee Traisathit, Virat Klinbuayaem, Prapan Sabsanong, Prateep Kanjanavikai, Gonzague Jourdain, Kenneth Mcintosh, Suporn Koetsawang. 1. aUnité Mixte Internationale 174, Institut de Recherche pour le Développement (IRD)-PHPT, Chiang Mai, Thailand bDepartment of Immunology and Infectious, Diseases, Harvard School of Public Health, Boston, Massachusetts, USA cDepartment of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand dUnité Mixte de Recherche 196, Centre Français de la Population et du Développement, (INED-IRD-Paris V University), Paris, France eDepartment of Statistics, Faculty of Science, Chiang Mai University, Chiang Mai fSanpatong Hospital, Ministry of Public Health, Sanpatong gSamutprakarn Hospital, Ministry of Public Health, Samutprakarn hBanglamung Hospital, Ministry of Public Health, Chonburi, Thailand iChildren's Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA jFamily Health Research Center, Mahidol University, Bangkok, Thailand.
Abstract
OBJECTIVES: Perinatal single-dose nevirapine (sdNVP) selects for resistance mutations. The objective of this trial was to compare two maternal sdNVP-sparing regimens with standard zidovudine (ZDV)/sdNVP prophylaxis. DESIGN: PHPT-5 was a randomized, partially double-blind placebo-controlled, noninferiority trial in Thailand (NCT00409591). Study participants were women with CD4 of at least 250 cells/μl and their infants. METHODS: All women received ZDV from 28 weeks' gestation and their newborn infants for one week. Women were also randomized to receive NVP-NVP (reference): maternal intrapartum sdNVP with a 7-day 'tail' of ZDV along with lamivudine, and infant NVP (one dose immediately, another 48 h later); infant-only NVP: maternal placebos for sdNVP and the 'tail', with infant NVP; LPV/r: maternal LPV/r starting at 28 weeks. Infants were formula-fed. HIV-diagnosis was determined by DNA-PCR. RESULTS:Four-hundred and thirty-five women were randomized between January 2009 and September 2010. Accrual was terminated prematurely following a change in Thai guidelines recommending antiretroviral combination therapy for all pregnant women. Data on 405 mothers and 407 live-born children were analyzed. Baseline characteristics were similar between arms. Intent-to-treat transmission rates were 3.8% (95% confidence interval: 1.2-8.6) in NVP-NVP, 1.6% (0.2-5.6) in infant-only NVP, and 1.4% (0.4-5.1) in LPV/r arms. As-treated rates were 2.2% (0.5-6.4), 3.2% (0.9-7.9), and 1.5% (0.2-5.2), respectively. Factors independently associated with transmission were prophylaxis duration less than 8 weeks (adjusted odds ratio 15.5; 3.6-66.1) and viral load at baseline at least 4 log10copies/ml (adjusted odds ratio 10.9; 1.3-91.5). Regimens appeared well tolerated. CONCLUSION:Transmission rates in all arms were low but noninferiority was not proven. Antiretroviral prophylaxis for at least 8 weeks before delivery is necessary to minimize transmission risk.
RCT Entities:
OBJECTIVES: Perinatal single-dose nevirapine (sdNVP) selects for resistance mutations. The objective of this trial was to compare two maternal sdNVP-sparing regimens with standard zidovudine (ZDV)/sdNVP prophylaxis. DESIGN: PHPT-5 was a randomized, partially double-blind placebo-controlled, noninferiority trial in Thailand (NCT00409591). Study participants were women with CD4 of at least 250 cells/μl and their infants. METHODS: All women received ZDV from 28 weeks' gestation and their newborn infants for one week. Women were also randomized to receive NVP-NVP (reference): maternal intrapartum sdNVP with a 7-day 'tail' of ZDV along with lamivudine, and infant NVP (one dose immediately, another 48 h later); infant-only NVP: maternal placebos for sdNVP and the 'tail', with infant NVP; LPV/r: maternal LPV/r starting at 28 weeks. Infants were formula-fed. HIV-diagnosis was determined by DNA-PCR. RESULTS: Four-hundred and thirty-five women were randomized between January 2009 and September 2010. Accrual was terminated prematurely following a change in Thai guidelines recommending antiretroviral combination therapy for all pregnant women. Data on 405 mothers and 407 live-born children were analyzed. Baseline characteristics were similar between arms. Intent-to-treat transmission rates were 3.8% (95% confidence interval: 1.2-8.6) in NVP-NVP, 1.6% (0.2-5.6) in infant-only NVP, and 1.4% (0.4-5.1) in LPV/r arms. As-treated rates were 2.2% (0.5-6.4), 3.2% (0.9-7.9), and 1.5% (0.2-5.2), respectively. Factors independently associated with transmission were prophylaxis duration less than 8 weeks (adjusted odds ratio 15.5; 3.6-66.1) and viral load at baseline at least 4 log10copies/ml (adjusted odds ratio 10.9; 1.3-91.5). Regimens appeared well tolerated. CONCLUSION: Transmission rates in all arms were low but noninferiority was not proven. Antiretroviral prophylaxis for at least 8 weeks before delivery is necessary to minimize transmission risk.
Authors: Annemiek de Ruiter; Graham P Taylor; Polly Clayden; Jyoti Dhar; Kate Gandhi; Yvonne Gilleece; Kate Harding; Phillip Hay; Jane Kennedy; Naomi Low-Beer; Hermione Lyall; Adrian Palfreeman; Siobhan O'Shea; Pat Tookey; Jennifer Tosswill; Steven Welch; Ed Wilkins Journal: HIV Med Date: 2014-09 Impact factor: 3.180
Authors: Shahin Lockman; Michael D Hughes; James McIntyre; Yu Zheng; Tsungai Chipato; Francesca Conradie; Fred Sawe; Aida Asmelash; Mina C Hosseinipour; Lerato Mohapi; Elizabeth Stringer; Rosie Mngqibisa; Abraham Siika; Diana Atwine; James Hakim; Douglas Shaffer; Cecilia Kanyama; Kara Wools-Kaloustian; Robert A Salata; Evelyn Hogg; Beverly Alston-Smith; Ann Walawander; Eva Purcelle-Smith; Susan Eshleman; James Rooney; Sibtain Rahim; John W Mellors; Robert T Schooley; Judith S Currier Journal: N Engl J Med Date: 2010-10-14 Impact factor: 91.245
Authors: Shino Arikawa; Nigel Rollins; Gonzague Jourdain; Jean Humphrey; Athena P Kourtis; Irving Hoffman; Max Essex; Tim Farley; Hoosen M Coovadia; Glenda Gray; Louise Kuhn; Roger Shapiro; Valériane Leroy; Robert C Bollinger; Carolyne Onyango-Makumbi; Shahin Lockman; Carina Marquez; Tanya Doherty; François Dabis; Laurent Mandelbrot; Sophie Le Coeur; Matthieu Rolland; Pierre Joly; Marie-Louise Newell; Renaud Becquet Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Jesse F Mangold; Ria Goswami; Ashley N Nelson; David R Martinez; Genevieve G Fouda; Sallie R Permar Journal: Pediatr Infect Dis J Date: 2021-05-01 Impact factor: 3.806